US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NeOnc Technologies Holdings

7.83

-1.6100-17.06%

Volume:61.00K

Turnover:534.77K

Market Cap:152.48M

PE:-2.95

High:9.81

Open:9.55

Low:7.71

Close:9.44

52wk High:25.00

52wk Low:3.20

Shares:19.47M

Float Shares:6.00M

Volume Ratio:0.92

T/O Rate:1.02%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.6573

EPS(LYR):-0.6861

ROE:--

ROA:-853.56%

PB:-12.91

PE(LYR):-11.41

Loading ...

Overview Company News Filings

NeOnc Technologies Reports Promising Remission Results for Intranasal NEO100 in Recurrent IDH1-Mutant Astrocytoma

NeOnc Technologies Reports Promising Remission Rates in Phase 2 Trial of Intranasal NEO100 for Recurrent IDH1-Mutant Gliomas

NeOnc Technologies Unveils AI-Driven Study Showing Ultrasound Boosts NEO100 Potency Against Brain Tumors

NeOnc Technologies Unveils AI-Driven Study Showing Ultrasound Boosts NEO100 Potency Against Brain Tumors

Neonc Technologies Holdings Inc. Files Initial Beneficial Ownership Statement for Director Ming-Fu (Alan) Chiang

Chief Clinical Officer Yousha Neman-Ebrahim Acquires Common Shares of Neonc Technologies Holdings Inc

NeOnc Technologies Q3 EPS $(0.45)

NeOnc Technologies Holdings reports Q3 net loss of $8.6 million on higher expenses

Neonc Technologies Holdings Inc - Reports Q3 Net Loss of $8.6 Mln or $0.45 per Share

THOMSON REUTERS

NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update

NeOnc Technologies Completes Enrollment in Phase 2a Trial for NEO100 in Recurrent High-Grade Glioma

Neonc Technologies Holdings Inc - No Significant Toxicity With Prolonged Intranasal Neo100 Administration

THOMSON REUTERS

Neonc Technologies Holdings Inc - Neo100 Shows 21% Radiographic Response in Recurrent Gliomas

THOMSON REUTERS

Neonc Technologies Holdings Inc - 44% Achieved Six-Month Progression-Free Survival, Surpassing Benchmark

THOMSON REUTERS

NeOnc Technologies Reports Promising Clinical Results for Intranasal NEO100 in Recurrent IDH1-Mutant Gliomas

NeOnc Technologies Announces Data Updates from Ongoing NEO100-1 Brain Tumor Clinical Trial

NeOnc Technologies Names Amir Heshmatpour as CEO

Neonc Technologies Appoints Amir Heshmatpour as Chief Executive Officer to Drive Next Phase of Clinical and Corporate Growth

THOMSON REUTERS

NeOnc Technologies Subsidiary NuroMENA Names Sheikh Nahyan bin Zayed Al Nahyan Executive Chairman

Press Release: His Highness Sheikh Nahyan bin Zayed Al Nahyan Assumes Executive Chairmanship of NeOnc Technologies' Subsidiary, NuroMENA, Pioneering UAE-US Partnership in Brain Cancer Treatment

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NTHI/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NTHI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NTHI\",,,,,undefined,":{"symbol":"NTHI","market":"US","secType":"STK","nameCN":"NeOnc Technologies Holdings","latestPrice":7.83,"timestamp":1766005200000,"preClose":9.44,"halted":0,"volume":60995,"delay":0,"floatShares":6000000,"shares":19474303,"eps":-2.657286,"marketStatus":"Pre-Mkt","change":-1.61,"latestTime":"12-18 08:45:11 EST","open":9.55,"high":9.81,"low":7.71,"amount":534765.3755,"amplitude":0.222458,"askPrice":11.66,"askSize":100,"bidPrice":3.14,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-2.657286,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766068200000},"marketStatusCode":1,"adr":0,"listingDate":1711512000000,"exchange":"NASDAQ","adjPreClose":7.83,"postHourTrading":{"tag":"盘后","latestPrice":7.83,"preClose":7.83,"latestTime":"16:10 EST","volume":1,"amount":7.83,"timestamp":1766005804806},"volumeRatio":0.9175077863453283},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NTHI\",,,,,undefined,":{"symbol":"NTHI","floatShares":6000000,"roa":"-853.56%","roe":"--","lyrEps":-0.686076,"volumeRatio":0.9175077863453283,"shares":19474303,"dividePrice":0,"high":9.81,"amplitude":0.222458,"preClose":9.44,"low":7.71,"week52Low":3.2,"pbRate":"-12.91","psRate":"2541.82","week52High":25,"institutionHeld":0,"latestPrice":7.83,"committee":0.333333,"eps":-2.657286,"divideRate":0,"volume":60995,"delay":0,"ttmEps":-2.657286,"open":9.55,"prevYearClose":25,"prevWeekClose":10.21,"prevMonthClose":8.95,"prevQuarterClose":9.08,"fiveDayClose":9.45,"twentyDayClose":7.06,"sixtyDayClose":11.88},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NTHI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-14","symbol":"NTHI","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-08-18","symbol":"NTHI","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1755489600000,"reportTimeType":"","actualEps":-0.3}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NTHI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NTHI\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NTHI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NTHI","date":"2025-12-17","current":-2.946615,"percent":0.451087,"low":-26.074295,"twenty":-5.408688,"median":-3.570116,"eighty":-2.258345,"high":-1.357276,"avg":-4.951923,"sd":4.269527,"marketCap":183837420},"quantilePoints":[{"date":"2024-03-28","current":-18.899455,"twenty":-18.899455,"median":-18.899455,"eighty":-18.899455,"marketCap":282000000},{"date":"2025-03-28","current":-18.905834,"twenty":-19.009816,"median":-18.905834,"eighty":-18.902007,"marketCap":224950380},{"date":"2025-04-04","current":-15.093157,"twenty":-20.260752,"median":-18.902645,"eighty":-16.151884,"marketCap":179585386},{"date":"2025-04-11","current":-14.179375,"twenty":-19.504518,"median":-17.739974,"eighty":-15.124667,"marketCap":168712785},{"date":"2025-04-17","current":-11.028403,"twenty":-19.044476,"median":-15.392499,"eighty":-12.855967,"marketCap":131221055},{"date":"2025-04-25","current":-9.437162,"twenty":-18.904558,"median":-14.667776,"eighty":-10.965384,"marketCap":112287731},{"date":"2025-05-02","current":-8.444606,"twenty":-18.667559,"median":-12.525115,"eighty":-9.437162,"marketCap":100477836},{"date":"2025-05-09","current":-10.398208,"twenty":-17.342951,"median":-11.028403,"eighty":-9.33318,"marketCap":123722709},{"date":"2025-05-16","current":-2.933338,"twenty":-15.682389,"median":-10.398208,"eighty":-8.444606,"marketCap":137753858},{"date":"2025-05-23","current":-2.969802,"twenty":-15.348385,"median":-9.44504,"eighty":-3.015179,"marketCap":139466268},{"date":"2025-05-30","current":-2.99006,"twenty":-15.171931,"median":-9.437162,"eighty":-2.969802,"marketCap":140417606},{"date":"2025-06-06","current":-3.034627,"twenty":-15.093157,"median":-9.311123,"eighty":-2.969802,"marketCap":142510552},{"date":"2025-06-13","current":-2.593006,"twenty":-14.242395,"median":-8.476116,"eighty":-2.937389,"marketCap":121771366},{"date":"2025-06-20","current":-1.928548,"twenty":-14.191979,"median":-7.853798,"eighty":-2.929004,"marketCap":90567453},{"date":"2025-06-27","current":-1.616577,"twenty":-12.855967,"median":-3.034627,"eighty":-2.802066,"marketCap":75916836},{"date":"2025-07-03","current":-2.362066,"twenty":-12.222621,"median":-3.010317,"eighty":-2.532985,"marketCap":110926104},{"date":"2025-07-11","current":-1.977167,"twenty":-11.425425,"median":-2.998163,"eighty":-2.362066,"marketCap":92850666},{"date":"2025-07-18","current":-1.786743,"twenty":-11.028403,"median":-2.99006,"eighty":-2.222692,"marketCap":83908082},{"date":"2025-07-25","current":-1.904238,"twenty":-10.981139,"median":-2.959854,"eighty":-1.949616,"marketCap":89425847},{"date":"2025-08-01","current":-1.98527,"twenty":-10.618776,"median":-2.937389,"eighty":-1.970684,"marketCap":93231202},{"date":"2025-08-08","current":-1.944754,"twenty":-10.133526,"median":-2.931642,"eighty":-1.939892,"marketCap":91328524},{"date":"2025-08-15","current":-2.102765,"twenty":-9.654579,"median":-2.909028,"eighty":-1.943134,"marketCap":98748967},{"date":"2025-08-22","current":-2.604584,"twenty":-9.443464,"median":-2.799635,"eighty":-1.954478,"marketCap":110548110},{"date":"2025-08-29","current":-3.15078,"twenty":-9.437162,"median":-2.795584,"eighty":-1.970684,"marketCap":133730643},{"date":"2025-09-05","current":-3.371966,"twenty":-9.437162,"median":-2.876616,"eighty":-1.980408,"marketCap":143118611},{"date":"2025-09-12","current":-4.405675,"twenty":-9.43086,"median":-2.918386,"eighty":-1.98527,"marketCap":186992991},{"date":"2025-09-19","current":-5.457439,"twenty":-9.377293,"median":-2.933338,"eighty":-1.993373,"marketCap":231633736},{"date":"2025-09-26","current":-4.681029,"twenty":-9.292217,"median":-2.939656,"eighty":-2.005528,"marketCap":198680053},{"date":"2025-10-03","current":-5.141458,"twenty":-8.961365,"median":-2.969802,"eighty":-2.008769,"marketCap":218222354},{"date":"2025-10-10","current":-5.407785,"twenty":-8.482417,"median":-2.99006,"eighty":-2.016872,"marketCap":229526233},{"date":"2025-10-17","current":-4.730683,"twenty":-8.444606,"median":-3.002214,"eighty":-2.039561,"marketCap":200787556},{"date":"2025-10-24","current":-3.769199,"twenty":-7.97196,"median":-3.022472,"eighty":-2.067922,"marketCap":159978635},{"date":"2025-10-31","current":-4.590749,"twenty":-7.105442,"median":-3.15078,"eighty":-2.071973,"marketCap":194848230},{"date":"2025-11-07","current":-4.446301,"twenty":-6.304447,"median":-3.298614,"eighty":-2.085748,"marketCap":188717312},{"date":"2025-11-14","current":-4.053582,"twenty":-5.457439,"median":-3.638293,"eighty":-2.120592,"marketCap":172048879},{"date":"2025-11-21","current":-2.32457,"twenty":-5.457439,"median":-3.482559,"eighty":-2.150574,"marketCap":113613569},{"date":"2025-11-28","current":-3.566132,"twenty":-5.449314,"median":-3.447134,"eighty":-2.162729,"marketCap":174295011},{"date":"2025-12-05","current":-3.725512,"twenty":-5.41591,"median":-3.522302,"eighty":-2.193521,"marketCap":182084733},{"date":"2025-12-12","current":-3.733481,"twenty":-5.411396,"median":-3.568124,"eighty":-2.214589,"marketCap":182474219},{"date":"2025-12-17","current":-3.761373,"twenty":-5.408688,"median":-3.570116,"eighty":-2.258345,"marketCap":183837420}],"updateTime":1766065511837},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NTHI\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2592943982","title":"NeOnc Technologies Reports Promising Remission Results for Intranasal NEO100 in Recurrent IDH1-Mutant Astrocytoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2592943982","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592943982?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:06","pubTimestamp":1766005585,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings Inc. has announced updated clinical results from its ongoing Phase 1/2a and compassionate-use experience evaluating intranasal NEO100 in patients with recurrent WHO Grade III/IV IDH1-mutant astrocytoma. The expanded clinical cohort now includes 25 patients, with updated results showing that intranasal NEO100 has resulted in radiographic remission in 6 of 25 patients (24%). This response rate is higher than the 8% typically reported with salvage therapies for recurrent high-grade gliomas. No significant toxicity has been observed with intranasal administration of NEO100, even with prolonged dosing. The updated clinical results were presented in the company's announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or lega","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL2wLqZ8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"gpt_icon":0},{"id":"2591644953","title":"NeOnc Technologies Reports Promising Remission Rates in Phase 2 Trial of Intranasal NEO100 for Recurrent IDH1-Mutant Gliomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2591644953","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591644953?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:00","pubTimestamp":1765807246,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings Inc. has announced updated clinical results from its ongoing Phase 1/2a and compassionate-use clinical experience evaluating intranasal NEO100 in patients with recurrent WHO Grade III/IV IDH1-mutant astrocytoma. The expanded clinical cohort now includes 25 patients, with results indicating significant radiographic remission in 6 of 25 patients (24%), which is higher than the 8% response rate typically reported with salvage therapies in recurrent high-grade gliomas. No significant toxicity has been observed with intranasal administration of NEO100, even with prolonged dosing. These updated results have already been presented by the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Hol","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL1KM3sP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0314104364.USD","LU2095319765.USD","SG9999014005.SGD","SG9999014039.USD","BK4585","IE00B64PRP62.GBP","IE00BKPKM429.USD","NDAQ","BK4007","BK4112","IE00BGHQF748.EUR","NTHI","IE00B3QW5Z07.USD","SG9999014013.SGD","LU2210150020.SGD","SG9999014021.USD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2589848365","title":"NeOnc Technologies Unveils AI-Driven Study Showing Ultrasound Boosts NEO100 Potency Against Brain Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2589848365","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589848365?lang=en_us&edition=fundamental","pubTime":"2025-12-06 06:01","pubTimestamp":1764972089,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings Inc.  announced newly published preclinical findings from a research collaboration at the University of Southern California. The study, now available on bioRxiv, indicates that the use of ultrasound enhances the therapeutic potency of NEO100 in treating primary and metastatic brain tumors. The research utilized an AI-driven, 3D-bioprinted methodology to rapidly generate patient-derived tumor organoids and demonstrated strong antitumor effects when NEO100 was combined with ultrasound. The results have already been presented through publication on bioRxiv.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via EDGAR, t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL60Dbs4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2588618773","title":"NeOnc Technologies Unveils AI-Driven Study Showing Ultrasound Boosts NEO100 Potency Against Brain Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2588618773","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588618773?lang=en_us&edition=fundamental","pubTime":"2025-12-01 22:00","pubTimestamp":1764597613,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings Inc.  announced newly published preclinical findings from a research collaboration at the University of Southern California  demonstrating that ultrasound enhances the potency of NEO100 in treating primary and metastatic brain tumors. The study, available on bioRxiv, utilized an AI-driven, 3D-bioprinted platform to identify NEO100 as a promising agent for sonodynamic therapy. Validation studies on patient-derived tumor organoids showed increased antitumor activity when NEO100 was combined with focused ultrasound. The company indicated that these results support advancing NEO100 with focused ultrasound into future clinical trials across various brain tumor types. Results have already been presented in the published preclinical study.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL8CvNwn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BKPKM429.USD","LU2095319765.USD","LU2210150020.SGD","BK4112","IE00B3QW5Z07.USD","LU0314104364.USD","IE00B64PRP62.GBP","NTHI","BK4588","NDAQ","IE00BGHQF748.EUR","BK4007","LU2210149790.SGD"],"gpt_icon":0},{"id":"2586141578","title":"Neonc Technologies Holdings Inc. Files Initial Beneficial Ownership Statement for Director Ming-Fu (Alan) Chiang","url":"https://stock-news.laohu8.com/highlight/detail?id=2586141578","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586141578?lang=en_us&edition=fundamental","pubTime":"2025-11-25 07:13","pubTimestamp":1764026025,"startTime":"0","endTime":"0","summary":"Neonc Technologies Holdings Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing names Ming-Fu  Chiang as a director and the reporting beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 24, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL7KY6d8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2586640415","title":"Chief Clinical Officer Yousha Neman-Ebrahim Acquires Common Shares of Neonc Technologies Holdings Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2586640415","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586640415?lang=en_us&edition=fundamental","pubTime":"2025-11-25 06:47","pubTimestamp":1764024435,"startTime":"0","endTime":"0","summary":"Yousha Neman-Ebrahim, Chief Clinical Officer of Neonc Technologies Holdings Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 24, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL7PRqTZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Chief Clinical Officer Yousha Neman-Ebrahim Acquires Common Shares of Neonc Technologies Holdings Inc","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2583668108","title":"NeOnc Technologies Q3 EPS $(0.45)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583668108","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583668108?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:04","pubTimestamp":1763154294,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Q3 EPS $(0.45)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48879667/neonc-technologies-q3-eps-0-45","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"NeOnc Technologies Q3 EPS $(0.45)","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2583814256","title":"NeOnc Technologies Holdings reports Q3 net loss of $8.6 million on higher expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2583814256","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583814256?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:01","pubTimestamp":1763154074,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings Inc. reported a net loss of $8.6 million, or $0.45 per diluted share, for the third quarter of 2025, compared to a net loss of $2.2 million, or $0.12 per diluted share, in the same period last year. General and administrative expenses increased to $903,000 from $244,000, while research and development expenses decreased to $715,000 from $957,000. During the period, the company advanced its NEO100 and NEO212 clinical programs, received $2.5 million in NIH STTR grants, expanded into the Middle East through new partnerships, and acquired advanced AI and 3D bioprinting intellectual property.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to gen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL6MdfQz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","NTHI","LU2210149790.SGD","IE00B64PRP62.GBP","LU0314104364.USD","BK4112","IE00B3QW5Z07.USD","LU2095319765.USD","BK4585","LU2210150020.SGD","IE00BGHQF748.EUR","BK4007","NDAQ","BK4588"],"gpt_icon":0},{"id":"2583681415","title":"Neonc Technologies Holdings Inc - Reports Q3 Net Loss of $8.6 Mln or $0.45 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2583681415","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583681415?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:01","pubTimestamp":1763154060,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nTUA36SJFL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NTHI"],"gpt_icon":0},{"id":"2583682461","title":"NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2583682461","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583682461?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:01","pubTimestamp":1763154060,"startTime":"0","endTime":"0","summary":"CALABASAS, Calif., Nov.  14, 2025  (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapie","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/14/3188596/0/en/NeOnc-Technologies-Holdings-Reports-Third-Quarter-2025-Results-and-Provides-Operational-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4135","NTHI","CNS"],"gpt_icon":0},{"id":"2583951595","title":"NeOnc Technologies Completes Enrollment in Phase 2a Trial for NEO100 in Recurrent High-Grade Glioma","url":"https://stock-news.laohu8.com/highlight/detail?id=2583951595","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583951595?lang=en_us&edition=fundamental","pubTime":"2025-11-13 22:00","pubTimestamp":1763042415,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings Inc. has announced the completion of patient enrollment in its Phase 2a clinical trial evaluating NEO100, a novel intranasal therapy, for the treatment of recurrent isocitrate dehydrogenase 1 -mutant high-grade glioma . The company previously presented positive results from a 24-patient cohort during an investor conference call on November 12, 2025. Preliminary data from the fully enrolled cohort are expected to be reported in the second quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on November 13, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL8KpWkf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4585","LU2210149790.SGD","BK4588","BK4007","IE00B64PRP62.GBP","LU2210150020.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","NTHI","NDAQ","IE00BKPKM429.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2582818371","title":"Neonc Technologies Holdings Inc - No Significant Toxicity With Prolonged Intranasal Neo100 Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=2582818371","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582818371?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:09","pubTimestamp":1762952941,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nFWN3WO0AZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2582371815","title":"Neonc Technologies Holdings Inc - Neo100 Shows 21% Radiographic Response in Recurrent Gliomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2582371815","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582371815?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:09","pubTimestamp":1762952941,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nFWN3WO0AZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2582337181","title":"Neonc Technologies Holdings Inc - 44% Achieved Six-Month Progression-Free Survival, Surpassing Benchmark","url":"https://stock-news.laohu8.com/highlight/detail?id=2582337181","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582337181?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:09","pubTimestamp":1762952941,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nFWN3WO0AZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2582239379","title":"NeOnc Technologies Reports Promising Clinical Results for Intranasal NEO100 in Recurrent IDH1-Mutant Gliomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2582239379","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582239379?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:00","pubTimestamp":1762952453,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings Inc. has announced updated clinical results from its ongoing Phase 1/2a and compassionate care studies evaluating the investigational intranasal agent NEO100 in patients with recurrent WHO Grade III/IV IDH1-mutant astrocytoma. The results, which were presented by the company, include a cohort of 24 patients and show that NEO100 treatment resulted in a significant radiographic response in 21% of patients, as confirmed by contrast-enhanced and perfusion MRI. Additionally, 44% of patients achieved six-month progression-free survival, and 33% remained alive at least 18 months after starting NEO100. The company also reported that no significant toxicity was observed with chronic intranasal administration of the agent. Full data readout is expected six months after full enrollment of the trial.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL5pjZVP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4007","LU0314104364.USD","BK4585","LU2095319765.USD","LU2210150020.SGD","IE00B64PRP62.GBP","BK4588","LU2210149790.SGD","NDAQ","NTHI","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112"],"gpt_icon":0},{"id":"2581588653","title":"NeOnc Technologies Announces Data Updates from Ongoing NEO100-1 Brain Tumor Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2581588653","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581588653?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:00","pubTimestamp":1762524032,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings Inc. , a clinical-stage biopharmaceutical company focused on novel therapeutics for malignant brain tumors and central nervous system disorders, has announced it will host an investor conference call and webcast on November 12, 2025. During the event, the company's management team and members of its Scientific Advisory Board will present data updates from the ongoing Phase 1/2a NEO100-1 clinical trial and compassionate use program. The study evaluates the intranasal delivery of NEO100  in patients with recurrent high grade malignant glioma. The discussion will include MRI-based radiographic response data, progression-free survival, and overall survival trends observed to date. Results from this clinical research will be presented during the upcoming call.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for infor","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL8gzmX0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IE00BGHQF748.EUR","BK4588","LU2095319765.USD","BK4112","LU0314104364.USD","NTHI","LU2210150020.SGD","IE00B3QW5Z07.USD","NDAQ","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210149790.SGD","BK4585"],"gpt_icon":0},{"id":"2580737778","title":"NeOnc Technologies Names Amir Heshmatpour as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2580737778","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580737778?lang=en_us&edition=fundamental","pubTime":"2025-11-04 22:00","pubTimestamp":1762264829,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings Inc. has appointed Amir Heshmatpour as Chief Executive Officer, in addition to his current roles as President and Executive Chairman. Dr. Thomas Chen, the company's founder, will transition from CEO to focus exclusively on his roles as Chief Medical Officer, Chief Scientific Officer, and board member.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on November 04, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDLYgtBP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4007","NTHI","LU2210149790.SGD","IE00B64PRP62.GBP","LU0314104364.USD","BK4588","LU2210150020.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","NDAQ","BK4585","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2580737033","title":"Neonc Technologies Appoints Amir Heshmatpour as Chief Executive Officer to Drive Next Phase of Clinical and Corporate Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2580737033","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580737033?lang=en_us&edition=fundamental","pubTime":"2025-11-04 22:00","pubTimestamp":1762264803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nTUA5H1VS8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2579108955","title":"NeOnc Technologies Subsidiary NuroMENA Names Sheikh Nahyan bin Zayed Al Nahyan Executive Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2579108955","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579108955?lang=en_us&edition=fundamental","pubTime":"2025-10-31 05:01","pubTimestamp":1761858072,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings Inc. announced that His Highness Sheikh Nahyan bin Zayed Al Nahyan has assumed the role of Executive Chairman of its Middle East subsidiary, NuroMENA Holdings Ltd. NuroMENA focuses on developing breakthrough treatments for brain cancer and other central nervous system malignancies. Amir Heshmatpour, previously Executive Chairman and President of NeOnc Technologies, will transition to Vice Chairman of NuroMENA.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 30, 2025, and is ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL3S9tFh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2578183952","title":"Press Release: His Highness Sheikh Nahyan bin Zayed Al Nahyan Assumes Executive Chairmanship of NeOnc Technologies' Subsidiary, NuroMENA, Pioneering UAE-US Partnership in Brain Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2578183952","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578183952?lang=en_us&edition=fundamental","pubTime":"2025-10-28 21:00","pubTimestamp":1761656400,"startTime":"0","endTime":"0","summary":"CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 28, 2025  -- NeOnc Technologies Holdings, Inc.  , a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system  cancers, announces a landmark development for global healthcare innovation, His Highness Sheikh Nahyan bin Zayed Al Nahyan, Chairman of the Zayed Charitable and Humanitarian Foundation, will formally assume the role of Executive Chairman of NuroMENA Holdings Ltd., the Middle East subsidiary of NeOnc Technologies Holdings, Inc. Amir Heshmatpour, current Executive Chairman and President of NeOnc Technologies, will transition to Vice Chairman of NuroMENA.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","CNS","BK4135","03160","BK4585","UAE","NTHI","BK4555","BK4007","TM","BK4099","BK4604"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":73,"code":"91000000","status":"200"}]}}